Cantor Fitzgerald Starts Agomab Therapeutics (AGMB) at Overweight
Tweet Send to a Friend
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Agomab ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


